Profile photo: William Maier

William Maier, PhD, PgD, MPH

Mapi’s Chief Scientific Officer has more than 20 years of drug development and commercialization experience

His promotion of a new pharmacoepidemiology, risk management, and research methodology—and his application of innovative technology to improve efficiency and accuracy of post-marketing surveillance studies—has proven invaluable to rare disease researchers. 

Dr. Maier has been involved in drug development and regulatory negotiations for products indicated for the following rare / orphan indications: 

  • Corneal cystine crystal deposits 
  • Stem Cell Mobilisation in Healthy Donors 
  • Severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS) following haematopoietic stem-cell transplantation (HSCT) therapy 
  • Primary Immunodeficiency (PI) in adults. This included, but was not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott- Aldrich syndrome, and severe combined immunodeficiencies 
  • Cystic Fibrosis 
  • Genetic variants of amyloid plaque development in Alzheimer’s Disease 
  • Primary and secondary progressive Multiple Sclerosis 
  • Crohn’s Disease and Ulcerative Colitis 
  • Autosomal dominant polycystic kidney disease (ADPKD) 
  • Levoleucovorin for Use In Combination Chemotherapy With 5-Fluorouracil In The Palliative Treatment Of Patients With Advanced Metastatic Colorectal Cancer: given orphan drug definition by FDA 

He has also conducted research projects for the follow rare disease areas:  

  • Cushing’s syndrome 
  • Duchenne’s muscular dystrophy (DMD) 
  • Progressive Multifocal Leukoencephalopathy (PML) 
  • Niemann-Pick type C disease 
  • Metastatic colorectal cancer (mCRC) 
  • Malignant glioma 
  • Short bowel syndrome (SBS) 
  • Dupuytren’s contracture 
  • Achondroplasia 
  • Multiple myeloma 
  • Transfusion-dependent anaemia due to myelodysplastic syndrome 
  • Insulin-like growth factor-1 Deficiency (IGF-1) 
  • Idiopathic pulmonary fibrosis (IPF) 
  • Hepatic encephalopathy chronic hypoparathyroidism 
  • N-Acetyl glutamate synthase deficiency 
  • Vitreomacular traction lipoprotein lipase-deficiency (LPL)

Employment History / Recent Positions

Consulting Companies

Actelion, ALK, Amgen, Aptalis, Astellas, AstraZeneca, BAT, Bayer, Biocodex, Celgene, Cortendo, Crucell, Elan Pharmaceutical, Ferring, Ipsen, J&J, Galderma, Gentium, GSK-Bio, Hospira, Ipsen, Laboratorie SMB, Lundbeck, Medtronic, Millenium, Mundipharma, Norgine, Pfizer, Retrophin, Roche, Sanofi, Sanofi-MSD, Santen, Schering- Plough, Shire, Sigma-Tau, Stallergene, Takeda, Targanta 

Member of European Medicines Agency sponsored Network of Centres of Excellence of Pharmacoepidemiology and Pharmacovigilance (ENCEPP) 

Employers

GSK, Elan Pharmaceutical, Pfizer (previously Parke-Davis), Parexel, PPD, Immunetech Pharmaceuticals 

Selected Disease Area Experience:

  • Post transplant lymphoprolifererative syndrome following liver transplant 
  • Post transplant lymphoprolifererative syndrome following renal transplant 
  • Post transplant lymphoprolifererative syndrome following heart transplant 
  • Behcets syndrome 
  • Chronic autoimmune thyroiditis and Graves’ Disease 
  • Auto immune haemolytic anaemia 
  • Antiphospholipid syndrome – primary 
  • Immune Thrombocytopenia Purpura 
  • Henoch-Schonlein Purpura 
  • Autoimmune neutropenia 
  • Myasthenia gravis 
  • Lambert Eaton myasthenic syndrome (LEMS) 
  • Stiff-person syndrome – amphiphysin-IgG 
  • Guillain-Barre syndrome (GBS) 
  • Optic neuritis 
  • Acute disseminated encephalomyelitis 
  • Chronic inflammatory demyelinating polyneuropathy 
  • Distal acquired demyelinating symmetric polyneuropathy (DADS) 
  • Coeliac disease 
  • Glomerulonephritis – IgA 
  • Pemphigus vulgaris 
  • Chronic idiopathic urticaria 
  • Vitiligo 
  • Systemic sclerosis / scleroderma, CREST syndrome 
  • Primary Sjogren’s disease / YeahSicca syndrome 
  • Dermatomyositis (DM) 
  • Reiter’s Arthritis 
  • Wegener’s granulomatosis 
  • Microscopic polyangitis (MPA) 
  • Polyarteritis nodosa primary systemic vasculitides 
  • Goodpasture’s syndrome (GPS) 
  • Thrombotic thrombocytopenic purpura (TTP) 
  • Juvenile rheumatoid arthritis 
  • Juvenile onset chronic polyarthritis / Still’s disease 
  • Lymphadenopathy Castleman disease (CD) 
  • Acute humoral (NONCELLUAR) graft rejection (AHR)

 

Education

University of Nottingham
Organisational Development / Tavistock Institute : PhD 

University of North Carolina at Chapel Hill
Epidemiology : PhD 

San Diego State University-California State University
Epidemiology, Biostatistics : MPH 

University of California, San Diego
Biochemistry and Cell Biology : Bachelor’s degree